Published in J Clin Pharmacol on June 01, 2007
Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med (2011) 6.79
HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr (2014) 2.43
The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 2.19
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). PLoS One (2014) 1.35
Preexposure prophylaxis for HIV prevention. Curr HIV/AIDS Rep (2011) 1.24
Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Antimicrob Agents Chemother (2008) 1.14
Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection. PLoS One (2012) 1.12
Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. Antimicrob Agents Chemother (2011) 1.09
Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2). Antimicrob Agents Chemother (2011) 1.09
Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. J Acquir Immune Defic Syndr (2014) 1.01
Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study. J Acquir Immune Defic Syndr (2014) 1.00
Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women. Antimicrob Agents Chemother (2011) 1.00
Effect of pregnancy on emtricitabine pharmacokinetics. HIV Med (2011) 0.91
Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial. AIDS Res Ther (2014) 0.89
Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients. Antimicrob Agents Chemother (2014) 0.89
Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism. CPT Pharmacometrics Syst Pharmacol (2014) 0.85
Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition. Antimicrob Agents Chemother (2011) 0.84
Very high concentrations of active intracellular phosphorylated emtricitabine in neonates (ANRS 12109 trial, step 2). Antimicrob Agents Chemother (2011) 0.83
Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies. J Clin Pharmacol (2013) 0.82
Challenges and opportunities in achieving bioequivalence for fixed-dose combination products. AAPS J (2012) 0.81
Modified renal function in pregnancy: impact on emtricitabine pharmacokinetics. Br J Clin Pharmacol (2014) 0.80
Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study. J Acquir Immune Defic Syndr (2016) 0.78
Emtricitabine Seminal Plasma and Blood Plasma Population Pharmacokinetics in HIV-Infected Men in the EVARIST ANRS-EP 49 Study. Antimicrob Agents Chemother (2015) 0.78
Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates. PLoS One (2016) 0.75
Evaluation of a multi-drug assay for monitoring adherence to a regimen for HIV pre-exposure prophylaxis in a clinical study (HIV Prevention Trials Network 073). Antimicrob Agents Chemother (2017) 0.75
Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. Pediatrics (2007) 1.08
Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state. Antimicrob Agents Chemother (2006) 1.00
Pharmacokinetic evaluation of emtricitabine in combination with other nucleoside antivirals in healthy volunteers. J Clin Pharmacol (2007) 0.99
Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother (2004) 0.93
Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients. AIDS (2005) 0.86
The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects. J Acquir Immune Defic Syndr (2016) 0.77
Pharmacokinetics of tacrolimus co-administered with adefovir dipivoxil to liver transplant recipients. Liver Int (2009) 0.75
Efficacy and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and renal impairment. J Clin Pharmacol (2010) 0.75